Frontier Capital Management Co. LLC Buys Shares of 298,052 Dyne Therapeutics, Inc. (NASDAQ:DYN)

Frontier Capital Management Co. LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 298,052 shares of the company’s stock, valued at approximately $7,022,000. Frontier Capital Management Co. LLC owned 0.29% of Dyne Therapeutics as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in DYN. Bank of New York Mellon Corp grew its position in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares in the last quarter. KBC Group NV increased its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the period. E Fund Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after buying an additional 1,249 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Dyne Therapeutics by 11.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after buying an additional 2,265 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $11.44 on Friday. The stock has a 50-day simple moving average of $10.37 and a 200-day simple moving average of $18.17. The company has a market capitalization of $1.30 billion, a P/E ratio of -3.21 and a beta of 1.19. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analysts Set New Price Targets

DYN has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright lowered their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.